Table 2.
Results of separate subgroups of group A before and 6 months after initiation of treatment; mean number of affected peripheral (PS) and central segments (CS) of neovascularization; corrected distance visual acuity (CDVA).
| Before treatment | 6 months after treatment (1 month in group 4) |
|||||||
|---|---|---|---|---|---|---|---|---|
| CDVA | PS | CS | CDVA | PS | CS | P | ||
| 1 | Pterygium (n = 6) | 0.85 (±0.21) | 8.5 (±5.12) | 0 | 0.9 (±0.18) | 6.66 (±4.49) | 0 | PS: 0.03 |
| CS: 0.2 | ||||||||
|
| ||||||||
| 2 | NV after penetrating keratoplasty (n = 8) | 0.02 (±0.04) | 41.25 (±17.42) | 1.75 (±1.78) | 0.05 (±0.08) | 30.5 (±11.37) | 1.25 (±1.45) | PS: 0.001 |
| CS: 0.02 | ||||||||
|
| ||||||||
| 3 | Other etiologies (n = 13) | 0.14 (±0.17) | 33.77 (±25.16) | 7.76 (±6.76) | 0.16 (±0.21) | 27.61 (±19.78) | 7.23 (±6.99) | PS: 0.000 |
| CS: 0.002 | ||||||||
|
| ||||||||
| 4 | Preparation for penetrating keratoplasty (n = 1) | 0.0001 | 14 | 0 | 0.001 | 7 | 0 | |